NICE Guidance on Mirvetuximab Ovarian Cancer Treatment

Mirvetuximab ovarian cancer treatment has taken a major step forward after NICE recommended mirvetuximab soravtansine for adults with folate receptor-alpha positive, platinum-resistant high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior regimens. The decision recognises clinically meaningful gains in both progression-free and overall survival compared with standard chemotherapy, with cost-effectiveness estimates falling within acceptable limits once disease severity is taken into account.

A three-state partitioned survival model with weekly cycles combined MIRASOL phase 3 trial results with Systemic Anti-Cancer Therapy registry records from 7,083 English patients. Independent parametric curves, extensive scenario testing on extrapolation distributions, utilities, adverse-event duration and vial-sharing assumptions produced a robust base case that satisfied both statistical fit and clinical expert input.

Registry Evidence Strengthens the Economic Case

Applying MIRASOL hazard ratios of 0.63 for progression-free survival and 0.68 for overall survival to a log-logistic curve fitted to real-world data (median overall survival 8.54 months) generated incremental quality-adjusted life years that justified routine NHS commissioning after the 1.2 severity weight was applied. NICE’s final recommendation highlights how real-world evidence can resolve extrapolation uncertainty in targeted oncology.

Quality-of-Life Gains That Matter to Patients

EQ-5D-5L data collected in MIRASOL showed consistent advantages for mirvetuximab soravtansine in both pre- and post-progression health states. Patient and carer testimony reinforced these findings, describing reduced fatigue, neuropathy and isolation compared with chemotherapy—insights that carried weight when formal carer disutility could not be fully quantified.

Lessons for Future Oncology Reimbursement

The appraisal underscores the value of early collection of NHS-aligned survival benchmarks and trial-derived utilities. Mirvetuximab ovarian cancer submissions should anticipate detailed scrutiny of post-progression assumptions, cycle-specific dosing intensity and vial-sharing feasibility, all of which influenced the final incremental cost-effectiveness ratio.